Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 285 participants.

Also called NCT07282743

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 285 participants (planned count) (from the registry)
Sponsor
Sun Pharmaceutical Industries Limited (from the registry)
Registry
  • NCT NCT07282743
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, India (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07282743. Randomized; triple masking; primary purpose treatment. Start 2026-01-20 (actual); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
Condition
Type II Diabetes Mellitus
Intervention (Drug)
GL0034 Dose Level 1
Intervention (Drug)
GL0034 Dose Level 2
Intervention (Drug)
GL0034 Dose Level 3
Intervention (Drug)
GL0034 Dose Level 4
Intervention (Drug)
GL0034 Dose Level 5
Intervention (Drug)
GL0034 Dose Level 6
Intervention (Other)
Placebo
Lead sponsor
Sun Pharmaceutical Industries Limited (class: industry)

Record details

Record id
cardio:ct-nct07282743
Content hash
776ff6194bdf547b595f5d9d8fec9d36e5c619b826467e483ca7bc29c83023c2